Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + olaparib
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pembrolizumab + olaparib is a combination therapy under investigation for the treatment of various advanced cancers, including metastatic pancreatic cancer with BRCA1/2 mutations, metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and homologous recombination deficiency (HRD)-positive advanced ovarian cancer. Pembrolizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2 to enhance immune-mediated tumor cell killing. Olaparib is a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair; by inhibiting PARP, it prevents tumor cells from repairing DNA damage, leading to cell death—especially in tumors with defects in homologous recombination repair such as those harboring BRCA mutations. The combination aims to exploit potential synergy between immune checkpoint inhibition and impaired DNA repair pathways[3][5][8].
- Brand names
- Lynparza (olaparib)Keytruda (pembrolizumab)
- Other names
- pembrolizumab + olaparib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PARP2 (Poly (adp-ribose) polymerase 2)PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on pembrolizumab + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + olaparib.